(Q30350341)

20 June 2017

1 reference

title

Agents and strategies in development for improved management of herpes simplex virus infection and disease. (English)

1 reference

20 June 2017

Gerald Kleymann

1

1 reference

PubMed ID

15757392

20 June 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Investigational Drugs

20 June 2017

1 reference

20 June 2017

14

1 reference

20 June 2017

2

1 reference

20 June 2017

135-161

1 reference

The seroepidemiology of herpes simplex virus type 1 and 2 in Europe

20 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Herpes simplex virus: receptors and ligands for cell entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Diagnosis of herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Type-specific testing for herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Therapeutic vaccination against chronic viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Molecular adjuvants for mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Recent progress in herpes simplex virus immunobiology and vaccine research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The host response to herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Imiquimod as a dermatological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Cytokines in experimental herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Human leukocyte interferon-alpha in a hydrophilic cream versus in a gel for the treatment of genital herpes in males: a placebo-controlled, double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Viruses and interferon: a fight for supremacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Therapeutics targeting the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Neonatal herpes simplex infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Clinical practice. Genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

New developments in the epidemiology, natural history and management of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

New antiviral nucleoside prodrugs await application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The evolution of antiviral therapy for external ocular viral infections over twenty-five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Treatment of viral diseases of the cornea and external eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Management of acyclovir-resistant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The herpesvirus proteases as targets for antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type 1 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Selective inhibition of herpes simplex virus ribonucleoside diphosphate reductase by derivatives of 2-acetylpyridine thiosemicarbazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Herpes simplex virus type 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The structural basis of specific base-excision repair by uracil-DNA glycosylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Prediction of the binding mode of N2-phenylguanine derivative inhibitors to herpes simplex virus type 1 thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Helicase primase: targeting the Achilles heel of herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

A generally applicable, high-throughput screening-compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

New anti-HSV therapeutics target the helicase-primase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Antiviral activity of CTC-8 against herpes simplex virus (HSV-1) in cell culture: evidence for a selective antiviral effect via a cellular mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Effect of Novobiocin and Other DNA Gyrase Inhibitors on Virus Replication and DNA Synthesis in Herpes Simplex Virus Type 1-infected BHK Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Cell culture replication of herpes simplex virus and, or human cytomegalovirus is inhibited by 3,7-dialkoxylated, 1-hydroxyacridone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Role of DNA topoisomerase I in the replication of herpes simplex virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Identification and characterization of the UL7 gene product of herpes simplex virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Herpes simplex virus-1 and varicella-zoster virus latency in ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Prevalence and distribution of HSV-1, VZV, and HHV-6 in human cranial nerve nuclei III, IV, VI, VII, and XII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Identification of a small molecule that inhibits herpes simplex virus DNA Polymerase subunit interactions and viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Use of antiviral drugs to prevent herpesvirus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

ME-609: A Treatment for Recurrent Herpes Simplex Virus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The structure and function of the HSV DNA replication proteins: defining novel antiviral targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Helicases as antiviral drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

DNA encapsidation as a target for anti-herpesvirus drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Development of new antivirals for herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

The effect of roscovitine on herpetic keratitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Antiherpes virus activities of new 6-19 carbon-bridged steroids and some synthetic precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.135

10.1517/13543784.14.2.135

21 January 2018

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

15757392